Adalimumab for maintenance of remission in Crohns disease Although these relapse rates are fairly high it should be noted that these participants had moderate‐to‐severe Crohn’s disease prior to induction of remission and many of these participants had failed treatment with other biologics (e g infliximab) or standard maintenance therapies (e g azathioprine or 6‐mercaptopurine) prior to